Search clinical trials for: CIN2

Total 52 results

University of Ibadan

Completed

Effect of Standardized Hibiscus Sabdariffa Tea in Seemingly Healthy Human Volunteers

Healthy Human Volunteers

Nigeria
Shanghai Bovax Biotechnology Co., Ltd.

Recruiting

Immune Persistence After the Whole Vaccination Shcedule With Recombination Quadrivalent HPV Vaccine

Vaginal Cancer | Cervical Cancer Stage IIa | CIN1 | CIN2 | CIN3 | Genital Wart | HPV Infections

China
Shanghai Bovax Biotechnology Co., Ltd.
Chongqing Bovax Biopharmaceutical Co., Ltd.

Completed

Evaluate the Immunogenicity and Safety of 4-valent and 9-valent HPV Recombinant Vaccine in Chinese Healthy Females

Cervical Cancer | Vulvar Cancer | Vaginal Cancer | CIN1 | CIN2 | CIN3 | VaIN1 | VaIN2 | VaIN3 | Genital Wart | VIN 1 | VIN 2 | VIN 3 | AIS

China
Universidade Cidade de Sao Paulo
Fundação de Amparo à Pesquisa do Estado de São Paulo

Completed

Management of Cervical Intraepithelial Neoplasia Grade 2 (CIN2)

Cervical Intraepithelial Neoplasia

Brazil
Tampon Innovations Ltd
University of Edinburgh; NHS Lothian

Not yet recruiting

Performance of Tampons as a Biospecimen Collection Tool for the Detection of Human Papillomavirus in a Colposcopy Setting (PETAHG)

CIN2
RinuaGene Biotechnology Co., Ltd.

Not yet recruiting

A Study in Subjects With Human Papillomavirus 16 or 18 Associated Cervical Intraepithelial Neoplasia Grade 2 or 3

Cervical Intraepithelial Neoplasia Grade 2/3 | Human Papillomavirus Associated Intraepithelial Neoplasia | Human Papillomavirus Type 16 Infection | Human Papillomavirus Type 18 Infection
Shanghai Bovax Biotechnology Co., Ltd.
Chongqing Bovax Biopharmaceutical Co., Ltd.

Recruiting

Immunogenicity and Safety of Quadrivalent HPV Vaccine in Healthy Chinese Female Subjects Aged 9 to 19 Years

Vaginal Cancer | Cervical Cancer Stage IIa | CIN1 | CIN2 | CIN3 | Genital Wart | HPV Infections

China
Shanghai Bovax Biotechnology Co., Ltd.
Chongqing Bovax Biopharmaceutical Co., Ltd.

Recruiting

Immunobridging Study of 9-valent Human Papillomavirus Recombinant Vaccine in Chinese Females Aged 9 to 19 Years

Cervical Cancer | Vulvar Cancer | Vaginal Cancer | CIN1 | CIN2 | VaIN1 | VaIN2 | VaIN3 | Genital Wart | VIN 1 | VIN 2 | VIN 3 | AIS | HPV Infections | CIN 3

China
University of Pretoria
University of Stellenbosch

Recruiting

Screening Study for Cervical Pre-cancer and Cancer Prevention in South African Women. (DiaVACCS)

Cervical Cancer | CIN2 | High Grade Sil

South Africa
Sahlgrenska University Hospital, Sweden

Completed

Expectancy as Alternative to Treatment for Cervical Intraepithelial Neoplasia Grade 2 Among Women 25 - 30 Years of Age (EXCIN2)

Therapy | CIN2

Sweden
Istituto Oncologico Veneto IRCCS
Azienda Ulss 2 Marca Trevigiana; Azienda ULSS 3 Serenissima; Regione Veneto; Azienda... and other collaborators

Completed

Conservative Management of CIN2 Lesions and Biomarkers Evaluation

CIN2

Italy
University Hospital, Bordeaux

Recruiting

Therapeutic Abstention and Surveillance of Intra-epithelial Histological Lesions of High Grade Cervical CIN2 (Cervical Intraepithelial Neoplasia Grade 2). SUIVICIN (SUIVICIN)

Cervical Cancer | HPV Infection

France
Inovio Pharmaceuticals

Completed

REVEAL 1 (Evaluation of VGX-3100 and Electroporation for the Treatment of Cervical HSIL) (REVEAL 1)

Cervical Dysplasia | Cervical High Grade Squamous Intraepithelial Lesion | HSIL

United States, Spain, Portugal, Italy, Philippines, Thailand, Slovakia, Lithuania, Estonia, Belgium, South Africa, Germany, Argentina, United Kingdom, Poland, Puerto Rico, Finland, Mexico, Peru
Inovio Pharmaceuticals

Completed

REVEAL 2 Trial (Evaluation of VGX-3100 and Electroporation for the Treatment of Cervical HSIL)

Cervical Dysplasia | Cervical High Grade Squamous Intraepithelial Lesion | HSIL

United States, Spain, Lithuania, Estonia, South Africa, Argentina, Brazil, Finland, Poland, Puerto Rico
General University Hospital, Prague

Recruiting

Regression of Cervical Precancerous Lesions and Associated Risk Factors (RECER)

HPV | CIN2 | CIN3 | Cervix Uteri SIL

Czechia
UNC Lineberger Comprehensive Cancer Center
National Cancer Institute (NCI)

Recruiting

Urine HPV Testing for Cervical Cancer Screening Among Women Living With HIV in South Africa

Cervical Cancer | CIN2 | CIN3

South Africa
UNC Lineberger Comprehensive Cancer Center
National Cancer Institute (NCI)

Recruiting

Acceptability and Feasibility of Combination Treatment for Cervical Precancer Among South African Women Living With HIV (ACT2)

Cervical Cancer | Human Immunodeficiency Virus | Human Papillomavirus | CIN2 | CIN3

South Africa
Shanghai Bovax Biotechnology Co., Ltd.

Recruiting

Evaluate the Efficacy, Immunogenicity and Safety of 9-valent HPV Recombinant Vaccine in Chinese Healthy Females

Cervical Cancer | Vulvar Cancer | Vaginal Cancer | CIN1 | CIN2 | CIN3 | VaIN1 | VaIN2 | VaIN3 | Genital Wart | VIN 1 | VIN 2 | VIN 3 | AIS

China
Shanghai Bovax Biotechnology Co., Ltd.

Terminated

A Phase Ⅲ Study to Evaluate the Efficacy, Immunogenicity, Safety of Quadrivalent HPV Recombinant Vaccine in Chinese Healthy Females

Cervical Cancer | CIN1 | CIN2 | CIN3 | Genital Wart | AIS | Vain I | Vain III | Vin I | Vin II | Vin III | VAIN - Vaginal Intraepithelial Neoplasia 2

China
International Agency for Research on Cancer

Active, not recruiting

Cervical Cancer Screening With Human Papillomavirus Testing (ESTAMPA)

Cervical Cancer | CIN2 | CIN3

Peru, Colombia, Argentina, Bolivia, Costa Rica, Honduras, Mexico, Paraguay, Uruguay
Shanghai Bovax Biotechnology Co., Ltd.
Chongqing Bovax Biopharmaceutical Co., Ltd.

Completed

Evaluate the Immunogenicity and Safety of 9-valent HPV Recombinant Vaccine in Chinese Healthy Females

Cervical Cancer | Vulvar Cancer | Vaginal Cancer | CIN1 | CIN2 | CIN3 | VaIN1 | VaIN2 | VaIN3 | Genital Wart | VIN 1 | VIN 2 | VIN 3 | AIS | HPV Infections

China
The University of Texas Health Science Center,...

Completed

Phase II Evaluation of AHCC for the Eradication of HPV Infections (AHCC4HPV)

Human Papilloma Virus | Dysplasia | CIN1 | CIN2

United States
Shanghai Bovax Biotechnology Co., Ltd.
Chongqing Bovax Biopharmaceutical Co., Ltd.

Completed

Evaluate the Safety and Primary Immunogenicity of 9-valent HPV Recombinant Vaccine in Chinese Healthy Females

Vulvar Cancer | Vaginal Cancer | CIN1 | CIN2 | VaIN1 | VaIN2 | VaIN3 | Genital Wart | AIS | Invasive Carcinoma | Cervical Cancers | CIN 3 | Vin III | Mild Dysplasia of Vulva | Moderate Dysplasia of Vulva

China
University of California, Los Angeles
National Cancer Institute (NCI); National Institutes of Health (NIH)

Completed

Natural History of HPV From Infection to Neoplasia in Adolescents and Young Women

Human Papillomavirus | CIN 3 | CIN 2

United States
Charles University, Czech Republic

Not yet recruiting

The Adjuvant Effect of HPV Vaccination on Recurrence of Cervical Precancer or Carcinoma in Women Undergoing Conization

Recurrence | Cervical Intraepithelial Neoplasia Grade 2/3

Czechia
University of Bern
International Agency for Research on Cancer; Centre for Infectious Disease... and other collaborators

Unknown

Screening Test Accuracy of Gynocular™, HR-HPV Testing, VIA for Detection of Cervical Neoplastic Lesions, in Women Living With HIV

Uterine Cervical Neoplasms | HIV/AIDS

Zambia
Genexine, Inc.

Unknown

Phase 2 Clinical Trial to Evaluate the Safety and Efficacy of Plasmid DNA Therapeutic Vaccine(GX-188E)

Cervical Intraepithelial Neoplasia

Korea, Republic of, Estonia, Ukraine
University of Aarhus
National Cancer Institute (NCI); University of Virginia; University of Cambridge and other collaborators

Active, not recruiting

Biomarkers Predictive for Cervical Intraepithelial Neoplasia Grade 2 (CIN2) Evolvement

Cervical Intraepithelial Neoplasia Grade 2 (CIN2)

Denmark
European Institute of Oncology

Not yet recruiting

Evaluation of the PreCursor-M+® in CIN2

Cervical Intraepithelial Neoplasia Grade 2

Italy
Inovio Pharmaceuticals

Completed

Fourth Dose of Human Papillomavirus (HPV) DNA Plasmid (VGX-3100) + EP in Adult Females Previously Vaccinated With Three Doses of VGX-3100

Human Papillomavirus (HPV)

Puerto Rico, United States
DySIS Medical Inc.

Completed

IMproved PRactice Outcomes and Value Excellence in Colposcopy (IMPROVE-COLPO)

High Grade Cervical Intraepithelial Neoplasia

United States
UNC Lineberger Comprehensive Cancer Center

Active, not recruiting

5-fluorouracil Following Cervical Intraepithelial Neoplasia Treatment Among HIV-positive Women in East Africa

HIV Infections | CIN 2/3

Kenya
Inovio Pharmaceuticals

Completed

Phase I of Human Papillomavirus (HPV) DNA Plasmid (VGX-3100) + Electroporation for CIN 2 or 3

Papillomavirus Infections

United States, Puerto Rico
Sidney Kimmel Comprehensive Cancer Center at Johns...
National Cancer Institute (NCI); National Institutes of Health (NIH)

Completed

Therapeutic Vaccination for Patients With HPV16+ Cervical Intraepithelial Neoplasia (CIN2/3)

HPV16 Positive | Cervical Intraepithelial Neoplasia (CIN 2/3)

United States
University Hospital, Bordeaux

Terminated

Prognostic Value of Human Papillomavirus (HPV) Detection in Cervical Intra-epithelial Neoplasia (CIN) Recurrence After Conization (SUIVICOL)

CIN2/3 Recurrence

France
Fujian Maternity and Child Health Hospital

Recruiting

Effect of HPV Integration on Prognosis of Young Women With CIN2 in China

Cervical Intraepithelial Neoplasia | HPV Infection | Virus Integration | HSIL, High Grade Squamous Intraepithelial Lesions

China
Nykode Therapeutics ASA
Theradex; Vaccibody AS

Completed

An Exploratory Safety and Immunogenicity Study of HPV16+ Immunotherapy VB10.16 in Women With HSIL; CIN 2/3)

High Grade Cervical Intraepithelial Neoplasia

Germany
Shenzhen People's Hospital

Unknown

DC Vaccines Targeting HPV16/18 E6/E7 Protein to Regress CINI/CIN2

Cervical Intraepithelial Neoplasia

China
Sidney Kimmel Comprehensive Cancer Center at Johns...
Frantz Viral Therapeutics

Completed

Intravaginal Artesunate for the Treatment of HPV+ High Grade Cervical Intraepithelial Neoplasia (CIN2/3)

Cervical Intraepithelial Neoplasia Grade 2/3 | High-risk HPV (Any Strain)

United States
BioLeaders Corporation

Unknown

A Trial to Evaluate the Efficacy and Safety of BLS-ILB-E710c in Patients With Cervical Intraepithelial Neoplasia 2/3 (CIN2/3)

Cervical Intraepithelial Neoplasia Grade 2/3

Korea, Republic of
Frantz Viral Therapeutics, LLC
M.D. Anderson Cancer Center; University of Michigan; The Cleveland Clinic; Amarex... and other collaborators

Recruiting

Artesunate Vaginal Inserts for the Treatment of Cervical Intraepithelial Neoplasia (CIN2/3) (ART-CIN_IIB)

HPV Infection | CIN 2/3 | Cervical Dysplasia | Pre-Cancerous Dysplasia | HPV Related Disease

United States
University Medical Center Groningen
Dutch Cancer Society; ViciniVax B.V

Completed

Vvax001 Cancer Vaccine in (Pre) Malignant Cervical Lesions

Cervical Cancer | CIN 2/3

Netherlands
AIDS Clinical Trials Group
National Institute of Allergy and Infectious Diseases (NIAID)

Completed

HPV Test-and-Treat-Strategy Versus Cytology-based Strategy for Prevention of CIN2+ in HIV-Infected Women

HIV-1 Infection

Peru, Malawi, South Africa, Zimbabwe, Haiti, Botswana, India
Mithra Pharmaceuticals

Completed

Safety and Efficacy Study of Antiviral Local Application to Treat High Grade Cervical Intraepithelial Lesions (CIN2/3) (Colvir-PhaseII)

Cervix Intraepithelial Neoplasia | Uterine Cervical Neoplasia

Belgium
University Medical Centre Maribor

Recruiting

The Role of FAM19A4 and Hsa-mir-124 Methylation in Predicting Prognosis of Untreated Cervical Intraepithelial Neoplasia 2 (CIN 2)

Cervical Intraepithelial Neoplasia Grade 2 | DNA Methylation

Slovenia
Brugmann University Hospital

Completed

A Prolongation of a Clinical Study to Evaluate the Efficacy of an Aqueous Gel Containing 2% (w/w) of Cidofovir, Directly Applied on the Cervix Exhibiting High Grade Squamous Intraepithelial Lesions.

High Grade Cervical Epithelial Neoplasia (CIN2+)

Belgium
Beijing Health Guard Biotechnology, Inc

Active, not recruiting

A Phase III Trial Evaluates the Efficacy, Immunogenicity and Safety Profile of HPV Vaccine

Human Papillomavirus Infection

China
Instituto Nacional de Saúde, Mozambique
M.D. Anderson Cancer Center

Not yet recruiting

Assessment of the Effectiveness of TA Versus LEEP for Cervical Cancer Risk Reduction in WLHIV in Mozambique

HIV Infections | HPV Infection | CIN 2/3

Mozambique
University of California, San Francisco
National Institutes of Health (NIH); Fogarty International Center of the National...

Completed

Thermocoagulation for Treatment of Precancerous Cervical Lesions

HPV Infection | Human Immunodeficiency Virus | CIN 2/3

Kenya
Miriam Elfström
Karolinska University Hospital

Recruiting

Concomitant HPV Vaccination and HPV Screening HPV Infection and Cervical Cancer in Sweden

Cervical Cancer | HPV Infection | CIN 2/3

Sweden

Search clinical trials for: CIN2

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Canada

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations